Cargando…
Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
SIMPLE SUMMARY: Myeloma, a blood cancer, is rare and hard to diagnose. People often suffer irreversible organ damage by the time of diagnosis. Myeloma is preceded by a premalignant phase that is easily identifiable on a blood test. Currently, there is no screening for this, because most people do no...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341254/ https://www.ncbi.nlm.nih.gov/pubmed/37444449 http://dx.doi.org/10.3390/cancers15133337 |
_version_ | 1785072218847313920 |
---|---|
author | Bowcock, Stella Atkin, Catherine Iqbal, Gulnaz Pratt, Guy Yong, Kwee Neal, Richard D. Planche, Tim Karunanithi, Kamaraj Jenkins, Stephen Stern, Simon Arnott, Sarah Toth, Peter Wandroo, Farooq Dunn, Janet Drayson, Mark T. |
author_facet | Bowcock, Stella Atkin, Catherine Iqbal, Gulnaz Pratt, Guy Yong, Kwee Neal, Richard D. Planche, Tim Karunanithi, Kamaraj Jenkins, Stephen Stern, Simon Arnott, Sarah Toth, Peter Wandroo, Farooq Dunn, Janet Drayson, Mark T. |
author_sort | Bowcock, Stella |
collection | PubMed |
description | SIMPLE SUMMARY: Myeloma, a blood cancer, is rare and hard to diagnose. People often suffer irreversible organ damage by the time of diagnosis. Myeloma is preceded by a premalignant phase that is easily identifiable on a blood test. Currently, there is no screening for this, because most people do not progress to myeloma. We aimed to inform guidelines and screening by refining our understanding of how patients developing myeloma describe their symptoms and how those symptoms relate to organ damage. We found that patients rarely describe ‘bone pain’ but simply ‘pain’. Low-impact crush fractures of the backbones appear to be under-recognised as abnormal. At least 30% of patients have irreversible organ damage at diagnosis. People who developed myeloma fared better if they had previously been diagnosed to have the premalignant condition. Screening based on certain symptoms, possibly combined with imaging and laboratory results, may speed up the diagnosis of myeloma. ABSTRACT: Multiple myeloma (MM) patients risk diagnostic delays and irreversible organ damage. In those with newly diagnosed myeloma, we explored the presenting symptoms to identify early signals of MM and their relationships to organ damage. The symptoms were recorded in patients’ own words at diagnosis and included diagnostic time intervals. Those seen by a haematologist >6 months prior to MM diagnosis were classified as precursor disease (PD). Most (962/977) patients provided data. Back pain (38%), other pain (31%) and systemic symptoms (28%) predominated. Patients rarely complain of ‘bone pain’, simply ‘pain’. Vertebral fractures are under-recognised as pathological and are the predominant irreversible organ damage (27% of patients), impacting the performance status (PS) and associated with back pain (odds ratio (OR) 6.14 [CI 4.47–8.44]), bone disease (OR 3.71 [CI 1.88–7.32]) and age >65 years (OR 1.58 [CI 1.15–2.17]). Renal failure is less frequent and associated with gastrointestinal symptoms (OR 2.23 [CI1.28–3.91]), age >65 years (OR 2.14 [CI1.28–3.91]) and absence of back pain (OR 0.44 [CI 0.29–0.67]). Patients with known PD (n = 149) had fewer vertebral fractures (p = 0.001), fewer adverse features (p = 0.001), less decline in PS (p = 0.001) and a lower stage (p = 0.04) than 813 with de novo MM. Our data suggest subgroups suitable for trials of ‘symptom-directed’ screening: those with back pain, unexplained pain, a general decline in health or low-impact vertebral compression fractures. |
format | Online Article Text |
id | pubmed-10341254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103412542023-07-14 Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial Bowcock, Stella Atkin, Catherine Iqbal, Gulnaz Pratt, Guy Yong, Kwee Neal, Richard D. Planche, Tim Karunanithi, Kamaraj Jenkins, Stephen Stern, Simon Arnott, Sarah Toth, Peter Wandroo, Farooq Dunn, Janet Drayson, Mark T. Cancers (Basel) Article SIMPLE SUMMARY: Myeloma, a blood cancer, is rare and hard to diagnose. People often suffer irreversible organ damage by the time of diagnosis. Myeloma is preceded by a premalignant phase that is easily identifiable on a blood test. Currently, there is no screening for this, because most people do not progress to myeloma. We aimed to inform guidelines and screening by refining our understanding of how patients developing myeloma describe their symptoms and how those symptoms relate to organ damage. We found that patients rarely describe ‘bone pain’ but simply ‘pain’. Low-impact crush fractures of the backbones appear to be under-recognised as abnormal. At least 30% of patients have irreversible organ damage at diagnosis. People who developed myeloma fared better if they had previously been diagnosed to have the premalignant condition. Screening based on certain symptoms, possibly combined with imaging and laboratory results, may speed up the diagnosis of myeloma. ABSTRACT: Multiple myeloma (MM) patients risk diagnostic delays and irreversible organ damage. In those with newly diagnosed myeloma, we explored the presenting symptoms to identify early signals of MM and their relationships to organ damage. The symptoms were recorded in patients’ own words at diagnosis and included diagnostic time intervals. Those seen by a haematologist >6 months prior to MM diagnosis were classified as precursor disease (PD). Most (962/977) patients provided data. Back pain (38%), other pain (31%) and systemic symptoms (28%) predominated. Patients rarely complain of ‘bone pain’, simply ‘pain’. Vertebral fractures are under-recognised as pathological and are the predominant irreversible organ damage (27% of patients), impacting the performance status (PS) and associated with back pain (odds ratio (OR) 6.14 [CI 4.47–8.44]), bone disease (OR 3.71 [CI 1.88–7.32]) and age >65 years (OR 1.58 [CI 1.15–2.17]). Renal failure is less frequent and associated with gastrointestinal symptoms (OR 2.23 [CI1.28–3.91]), age >65 years (OR 2.14 [CI1.28–3.91]) and absence of back pain (OR 0.44 [CI 0.29–0.67]). Patients with known PD (n = 149) had fewer vertebral fractures (p = 0.001), fewer adverse features (p = 0.001), less decline in PS (p = 0.001) and a lower stage (p = 0.04) than 813 with de novo MM. Our data suggest subgroups suitable for trials of ‘symptom-directed’ screening: those with back pain, unexplained pain, a general decline in health or low-impact vertebral compression fractures. MDPI 2023-06-25 /pmc/articles/PMC10341254/ /pubmed/37444449 http://dx.doi.org/10.3390/cancers15133337 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bowcock, Stella Atkin, Catherine Iqbal, Gulnaz Pratt, Guy Yong, Kwee Neal, Richard D. Planche, Tim Karunanithi, Kamaraj Jenkins, Stephen Stern, Simon Arnott, Sarah Toth, Peter Wandroo, Farooq Dunn, Janet Drayson, Mark T. Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial |
title | Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial |
title_full | Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial |
title_fullStr | Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial |
title_full_unstemmed | Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial |
title_short | Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial |
title_sort | presenting symptoms in newly diagnosed myeloma, relation to organ damage, and implications for symptom-directed screening: a secondary analysis from the tackling early morbidity and mortality in myeloma (teamm) trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341254/ https://www.ncbi.nlm.nih.gov/pubmed/37444449 http://dx.doi.org/10.3390/cancers15133337 |
work_keys_str_mv | AT bowcockstella presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT atkincatherine presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT iqbalgulnaz presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT prattguy presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT yongkwee presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT nealrichardd presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT planchetim presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT karunanithikamaraj presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT jenkinsstephen presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT sternsimon presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT arnottsarah presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT tothpeter presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT wandroofarooq presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT dunnjanet presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial AT draysonmarkt presentingsymptomsinnewlydiagnosedmyelomarelationtoorgandamageandimplicationsforsymptomdirectedscreeningasecondaryanalysisfromthetacklingearlymorbidityandmortalityinmyelomateammtrial |